heyde syndrome
Reading File
Finding Sources
Searching PubMed
Heyde syndrome aortic stenosis angiodysplasia von Willebrand
Searching the Web
Heyde syndrome pathophysiology diagnosis treatment 2024 2025
Reading File
Reading File
Searching PubMed
Heyde syndrome aortic stenosis angiodysplasia
Reading Article
PMID: 37555393
Reading File
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC12852504
Here is a comprehensive overview of Heyde syndrome:
Heyde Syndrome
Definition
Heyde syndrome is a triad of:
- Aortic stenosis (AS) - typically moderate to severe
- Gastrointestinal bleeding - from angiodysplasia (angioectasias), predominantly in the right colon, small bowel, and stomach
- Acquired von Willebrand syndrome (AVWS) type 2A - loss of high-molecular-weight (HMW) vWF multimers
First described by Edward Heyde in 1958, the pathophysiologic mechanism was not proposed until 1992 by Warkentin et al.
Pathophysiology
The central mechanism is shear stress-induced destruction of vWF:
- Blood passing through the stenotic aortic valve generates abnormally high turbulent shear forces
- These forces unfold the large vWF polymer from a globular into an elongated, asymmetric configuration, exposing the A2 domain
- ADAMTS13 (a vWF-cleaving protease) binds the A2 domain and cleaves the HMW multimers into smaller, less hemostatic fragments
- Loss of HMW vWF multimers impairs platelet adhesion and primary hemostasis - this is acquired vWD type 2A
- Patients with angiodysplastic lesions (fragile, dilated mucosal vessels prone to bleeding) cannot form adequate platelet plugs, leading to recurrent GI hemorrhage
The same mechanism can occur in other conditions that generate high circulatory shear stress: hypertrophic cardiomyopathy, left ventricular assist devices (LVADs) (23% prevalence of GI bleeding), and severe mitral regurgitation. - Sleisenger and Fordtran's GI and Liver Disease, p. 618
Epidemiology
- Uncommon and underrecognized, especially in elderly patients
- Predominantly affects older adults with degenerative/calcific AS
- The average duration of symptoms is approximately 23.8 months before diagnosis
Clinical Features
- GI bleeding: hematemesis, melena, or hematochezia from right colonic, small bowel, or gastric angiodysplasia
- Anemia: often iron-deficiency anemia from chronic occult blood loss
- Symptoms of AS: angina, syncope, dyspnea (heart failure) - the classic triad of severe AS
- Auscultation: crescendo-decrescendo systolic ejection murmur radiating to the neck; "pulsus parvus et tardus" in advanced disease
- Bleeding is often recurrent until the underlying valve disease is addressed
NSAIDs, aspirin, antiplatelet agents, and anticoagulants worsen bleeding and increase transfusion requirements. - Mulholland & Greenfield's Surgery, p. 4485
Diagnosis
A multidisciplinary approach (cardiology, gastroenterology, hematology) is required.
| Component | Test |
|---|---|
| GI bleeding / angiodysplasia | Endoscopy (colonoscopy, upper endoscopy), capsule endoscopy |
| Aortic stenosis | Echocardiography (gold standard) - measures jet velocity, mean gradient, valve area |
| Acquired vWD type 2A | vWF multimer assay (loss of HMW multimers), ristocetin cofactor activity, platelet function testing |
No universally accepted diagnostic criteria exist; variability in vWF assay interpretation limits diagnostic standardization. Laboratory findings often normalize rapidly after aortic valve replacement (AVR).
Treatment
Definitive - Aortic Valve Replacement (AVR)
AVR is the only treatment that addresses the root cause. The 2023 meta-analysis in the European Heart Journal (Goltstein et al., PMID 37555393) - the highest-quality evidence to date - found:
- 86-92% recovery of AVWS within hours to days of AVR (pooled across time points)
- 73% cessation of GI bleeding after AVR
- Residual aortic valve disease after AVR significantly reduced both AVWS recovery (RR 0.20) and GI bleeding cessation (RR 0.57)
Both surgical AVR and TAVR (transcatheter aortic valve replacement) are options; the choice depends on operative risk.
Medical and Endoscopic (Temporizing)
These provide only temporary benefit:
- Endoscopic therapy (argon plasma coagulation, thermal ablation) for active bleeding lesions
- Desmopressin - temporarily boosts vWF release
- Estrogen-progestin - used empirically to reduce angiodysplasia bleeding
- Octreotide - reduces splanchnic blood flow; useful in patients not suitable for AVR
- Blood transfusions, IV iron for anemia
- Tranexamic acid - antifibrinolytic adjunct
Current guidelines: AVR is recommended for severe symptomatic AS; it is not indicated solely for GI bleeding in the setting of asymptomatic AS, because most bleeding can be managed endoscopically. - Sleisenger and Fordtran, p. 618
Prognosis
- Recurrent GI bleeding is the norm without AVR
- Most patients achieve durable remission following successful valve replacement
- Residual valve disease after AVR (e.g., paravalvular leak) correlates with persistent AVWS and ongoing bleeding
Key Points Summary
| Feature | Detail |
|---|---|
| Triad | AS + GI angiodysplasia + acquired vWD type 2A |
| Mechanism | High shear stress → ADAMTS13 cleavage of HMW vWF multimers |
| Most common bleeding site | Right colon; also small bowel, stomach |
| Diagnostic tests | Echocardiography + endoscopy + vWF multimer assay |
| Definitive treatment | AVR (surgical or TAVR) |
| AVR success rate | ~87-92% AVWS resolution; ~73% GI bleeding cessation |
| Similar conditions | LVAD, HCM, severe mitral regurgitation |
This is a shared conversation. Sign in to Orris to start your own chat.